*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**DINGDANG HEALTH TECHNOLOGY GROUP LTD.**

**叮噹健康科技集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 09886)**

# CHANGE OF DIRECTORS AND CHANGE IN COMPOSITION OF THE BOARD COMMITTEES

The Board hereby announces that, with effect from July 21, 2026:

1. Ms. LI Chuheng has tendered her resignation as a non-executive Director of the Company and ceased to be a member of the Remuneration Committee and the Nomination Committee;

2. Ms. YANG Xiao has been appointed as an executive Director of the Company and a member of the Nomination Committee; and

3. Mr. JIANG Shan has been appointed as a member of the Remuneration Committee of the Company.

The board (the "**Board**") of directors (the "**Directors**") of Dingdang Health Technology Group Ltd. (the "**Company**", together with its subsidiaries and consolidated affiliated entities, the "**Group**") hereby announces the following changes of the Board.

## RESIGNATION OF NON-EXECUTIVE DIRECTOR

The Board hereby announces that Ms. LI Chuheng ("**Ms. LI**") has tendered her resignation as a non-executive Director of the Company and ceased to be a member of the Remuneration Committee and the Nomination Committee with effect from July 21, 2026 due to her intention to focus on other business engagements. Ms. LI has confirmed that she has no disagreement with the Board and that there are no other matters relating to her resignation that needs to be brought to the attention of the shareholders (the "**Shareholders**") of the Company or The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

The Board would like to express its sincere gratitude to Ms. LI for her valuable contribution to the Company during her tenure of office.

## APPOINTMENT OF EXECUTIVE DIRECTOR

The Board is pleased to announce that Ms. YANG Xiao ("**Ms. YANG**") has been appointed as an executive Director of the Company and a member of the Nomination Committee with effect from July 21, 2026.

The biographical details of Ms. YANG are set out as follows:

Ms. YANG, aged 35, joined the Group in July 2024 as the head of the treasury supervision department, responsible for treasury management. Prior to joining the Group, Ms. YANG served as the head of the treasury supervision department at the Beijing Office of Renhe (Group) Development Co., Ltd. from October 2020 to June 2024, and as the supervisor of the finance department of Jiangxi Renhe Zhongfang Pharmaceutical Co., Ltd. from July 2012 to September 2020.

Ms. YANG obtained the college diploma in financial management from Nanchang University in Nanchang, China in January 2023.

Ms. YANG has entered into a service contract with the Company for an initial term of three years with effect from July 21, 2026, which is renewable automatically for successive terms of three years commencing on the day after the expiry of the then existing term and may be terminated by not less than three months' notice in writing served by either party on the other. Ms. YANG will hold office until the first annual general meeting of the Company after her appointment and be eligible for re-election in accordance with the articles of association of the Company. Ms. YANG does not receive any Director's fees as an executive Director, except for the remuneration for her other positions held within the Group.

Save as disclosed above, as at the date of this announcement, Ms. YANG (a) does not have any interests in the shares, underlying shares or debentures of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (b) has not held any directorships in any other listed public companies in Hong Kong or overseas in the last three years preceding the date of her appointment, and does not hold any other major appointments and professional qualifications; (c) does not have any relationship with any Director, senior management, substantial Shareholder or controlling Shareholder of the Company (as defined under the Listing Rules); and (d) does not hold any other position with the Company or any member of the Group.

Save as disclosed above, there are no other matters which need to be brought to the attention of the Shareholders of the Company regarding the appointment of Ms. YANG or any other information which is required to be disclosed pursuant to Rule 13.51(2)(h) to 13.51(2)(v) of the Rules Governing the Listing of Securities on the Stock Exchange.

The Board would like to take this opportunity to express its warm welcome to Ms. YANG for joining the Board.

**CHANGE IN COMPOSITION OF THE REMUNERATION COMMITTEE**

The Board further announces that Mr. JIANG Shan, an independent non-executive Director, has been appointed as a member of the Remuneration Committee of the Company with effect from July 21, 2026.

By order of the Board
**DINGDANG HEALTH TECHNOLOGY GROUP LTD.**
*Chairman*
**YANG WENLONG**

Hong Kong, July 21, 2026

*As of the date of this announcement, the executive Directors are Mr. YANG Wenlong, Mr. YANG Yibin, Mr. XU Ning, Mr. YU Qinglong, Mr. MENG Fanzhou and Ms. YANG Xiao, and the independent non-executive Directors are Mr. ZHANG Shouchuan, Dr. FAN Zhenhong and Mr. JIANG Shan.*